Cytarabine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Cytarabine and local guidelines before prescribing.
Antimetabolite cytotoxic
Mechanism
Pyrimidine antimetabolite.
Uses
Acute myeloid leukaemia, lymphoma, meningeal leukaemia (intrathecal).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Marrow suppression, cerebellar toxicity, conjunctivitis, fever, rash.
Interactions
Digoxin absorption reduced.
Contraindications and cautions
Severe marrow suppression
Monitoring
FBC, LFT, neurology
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Steroid eye drops with high doses; neurological checks.
More from the textbook: uses, cautions and other points
- Cytarabine (high dose) - cerebellar toxicity, conjunctivitis (steroid eye drops).
Haematology: Anatomy Physiology and Pharmacology - Cytarabine + daunorubicin ("7+3") | AML induction; myelosuppression; cardiotoxicity (anthracycline).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Cerebellar ataxia | Phenytoin , carbamazepine, lithium , alcohol, metronidazole (encephalopathy), chemotherapy (cytarabine, 5-FU)
Neurology: Anatomy, Physiology and Pharmacology - Induction ("7+3" - cytarabine with daunorubicin), plus targeted drugs (e.g. midostaurin for FLT3-mutated AML, gemtuzumab ozogamicin for some favourable types).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Fit patients: cytarabine-containing immunochemotherapy (for example R-CHOP alternating with R-DHAP), often with autologous stem cell transplant, then rituximab maintenance.
Haematology: Myeloma and Lymphoma - Cell-cycle-specific chemotherapy: antimetabolites (methotrexate, 5-FU, cytarabine) - S phase; vinca alkaloids and taxanes - M phase; bleomycin - G2; etoposide - S/G2 (topoisomerase II). Cell-cycle non-specific: alkylating agents (cyclophosphamide), platinum compounds, anthracyclines.
Cell Biology: Cell cycle, signalling, cell death and stem cells
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (2 mentions)
- Haematology: Myeloma and Lymphoma (1 mention)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)